There are currently 178 clinical trials in Wichita, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including CCOP - Wichita, Cancer Center of Kansas-Wichita Medical Arts Tower, Cancer Center of Kansas - Wichita and Associates in Womens Health. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
NCT06272487
Recruiting
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Clinical Trial Site, Wichita, Kansas
Conditions: High Cardiovascular Risk, Hypertension
Register for Updates
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT04530110
Recruiting
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/07/2024
Locations: Teva Investigational Site 14245, Wichita, Kansas
Conditions: Migraine
Register for Updates
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034
Recruiting
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Ascension Via Christi Hospitals Wichita, Wichita, Kansas +1 locations
Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Register for Updates
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT06106308
Recruiting
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Cancer Center of Kansas, Wichita, Kansas
Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Cancer Center of Kansas, Wichita, Kansas
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Safety and Effectiveness of Juveena™ Hydrogel System Following TCGP At High-Risk for Intrauterine Adhesions
NCT05394662
Recruiting
This study is to determine whether intrauterine instillation of Juveena hydrogel following adhesiogenic hysteroscopic procedures (TCGP + Juveena) can safely and effectively reduce the incidence and severity of intrauterine adhesions (IUA) compared to TCGP alone.
Gender:
Female
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Cypress Medical Research Center, Wichita, Kansas
Conditions: Intrauterine Adhesion
Register for Updates
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615
Recruiting
The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Cardiovascular Research Institute of Kansas, Wichita, Kansas
Conditions: Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Register for Updates
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05521191
Recruiting
Primary Objectives To assess the safety and tolerability of RGLS8429 To assess the impact of RGLS8429 on ADPKD biomarkers Secondary Objectives To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) To characterize the pharmacokinetic (PK) properties of RGLS8429 To assess the impact of RGLS8429 on renal function
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
04/27/2024
Locations: Witchita Nephrology Group, PA, Wichita, Kansas
Conditions: Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
All
Ages:
65 years and above
Trial Updated:
04/26/2024
Locations: Cardiovascular Research Institute of Kansas, Wichita, Kansas
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
NCT05254834
Recruiting
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
Gender:
All
Ages:
30 years and above
Trial Updated:
04/26/2024
Locations: Ascension Via Christi Hospital, Wichita, Wichita, Kansas
Conditions: Cancer
Register for Updates
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
NCT05557409
Recruiting
This trial is a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
Gender:
All
Ages:
Between 65 years and 90 years
Trial Updated:
04/25/2024
Locations: Clinical Research Site, Wichita, Kansas
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2024
Locations: Research Site, Wichita, Kansas
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates